Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease - Trial NCT06053424
Access comprehensive clinical trial information for NCT06053424 through Pure Global AI's free database. This Phase 1 trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Crohn's Disease. Target enrollment is 12 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
AstraZeneca
Timeline & Enrollment
Phase 1
Sep 25, 2023
May 06, 2024
Primary Outcome
Change from baseline in small bowel SUV/SUVR
Summary
The purpose of this study is to measure the changes in small bowel uptake of radioligand
 [11C]AZ14132516 after IV administration of a single dose of AZD7798 in healthy participants
 and participants with Crohn's disease.
 
 Study details include:
 
 - The study duration will be variable (adaptive design).
 
 - There will be 5 in-person study visits: 1 screening visit, 1 visit for the baseline PET
 examination, 1 residential (24h) visit for AZD7798 administration and 2 visits for
 repeated PET examinations. There will be a final follow-up virtual visit (telephone
 call).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06053424
Non-Device Trial